Press Releases

Date Title and Summary Additional Formats
Toggle Summary NOVELOS THERAPEUTICS ANNOUNCES DISMISSAL OF PUTATIVE FEDERAL SECURITIES CLASS ACTION LAWSUIT
NOVELOS THERAPEUTICS ANNOUNCES DISMISSAL OF PUTATIVE FEDERAL SECURITIES CLASS ACTION LAWSUIT MADISON, WI, June 28, 2011 – Novelos Therapeutics, Inc. (OTCBB: NVLT), a pharmaceutical company developing novel drugs for treatment and diagnosis of cancer, today announced that on June 23, 2011,
View HTML
Toggle Summary NOVELOS THERAPEUTICS TO PRESENT AT THE 5th LIPPERT/HEILSHORN LIFE SCIENCES & MEDICAL TECHNOLOGIES VIRTUAL CONFERENCE ON JUNE 16
NOVELOS THERAPEUTICS TO PRESENT AT THE 5th LIPPERT/HEILSHORN LIFE SCIENCES & MEDICAL TECHNOLOGIES VIRTUAL CONFERENCE ON JUNE 16 MADISON, WI, June 13, 2011 – Novelos Therapeutics, Inc. (OTCBB: NVLT), a pharmaceutical company developing novel drugs for treatment and diagnosis of cancer, today
View HTML
Toggle Summary NOVELOS THERAPEUTICS TRADING SYMBOL REVERTS TO NVLT
NOVELOS THERAPEUTICS TRADING SYMBOL REVERTS TO NVLT MADISON, WI, May 9, 2011 – Novelos Therapeutics, Inc. (OTCBB: NVLT), a pharmaceutical company developing novel drugs for treatment and diagnosis of cancer, announced that today its trading symbol has reverted to NVLT.
View HTML
Toggle Summary NOVELOS THERAPEUTICS WELCOMES FIVE NEW DIRECTORS
NOVELOS THERAPEUTICS WELCOMES FIVE NEW DIRECTORS MADISON, WI, April 26, 2011 – Novelos Therapeutics, Inc. (OTCBB: NVLTD), a pharmaceutical company developing novel drugs for treatment and diagnosis of cancer, today announced that Dr. Rock Mackie, Mr. John Neis, Dr. John Niederhuber, Dr.
View HTML
Toggle Summary NOVELOS THERAPEUTICS COMPLETES ACQUISITION AND $5.1 MILLION FINANCING TO DEVELOP 3 NOVEL CANCER-TARGETED COMPOUNDS
Trading Under Symbol NVLTD for 20 Trading Days to Reflect Reverse Split
View HTML